Roche Holding confirmed its 2023 guidance after a fall in sales for the first nine months, with growth in its pharmaceutical division overshadowed by a sharp drop in diagnostics sales due to weaker Covid-19-related demand.
The Swiss pharma giant said Thursday that sales for the first nine months of the year amounted to 44.05 billion Swiss francs ($49 billion), down 6% on year. Sales at the company’s pharma division rose 1%, and diagnostics sales fell 25%.
Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8